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Protocol
AbstrACt
Introduction Pneumococcal conjugate vaccines 
(PCVs) prevent disease through both direct protection 
of vaccinated individuals and indirect protection of 
unvaccinated individuals by reducing nasopharyngeal 
(NP) carriage and transmission of vaccine-type (VT) 
pneumococci. While the indirect effects of PCV vaccination 
are well described, the PCV coverage required to achieve 
the indirect effects is unknown. We will investigate the 
relationship between PCV coverage and VT carriage 
among undervaccinated children using hospital-based NP 
pneumococcal carriage surveillance at three sites in Asia 
and the Pacific.
Methods and analysis We are recruiting cases, defined 
as children aged 2–59 months admitted to participating 
hospitals with acute respiratory infection in Lao People’s 
Democratic Republic, Mongolia and Papua New Guinea. 
Thirteen-valent PCV status is obtained from written 
records. NP swabs are collected according to standard 
methods, screened using lytA qPCR and serotyped by 
microarray. Village-level vaccination coverage, for the 
resident communities of the recruited cases, is determined 
using administrative data or community survey. Our 
analysis will investigate the relationship between VT 
carriage among undervaccinated cases (indirect effects) 
and vaccine coverage using generalised estimating 
equations.
Ethics and dissemination Ethical approval has 
been obtained from the relevant ethics committees 
at participating sites. The results are intended for 
publication in open-access peer-reviewed journals and will 
demonstrate methods suitable for low- and middle-income 
countries to monitor vaccine impact and inform vaccine 
policy makers about the PCV coverage required to achieve 
indirect protection.
IntroduCtIon 
Infections due to Streptococcus pneumoniae 
(the pneumococcus), including pneumonia, 
meningitis and septicaemia, are a leading 
cause of morbidity and mortality among 
children and elderly, especially in low- and 
middle-income countries (LMIC).1 The main 
reservoir for the pneumococcus is the human 
nasopharynx. Pneumococcal carriage peaks 
in young children, an important group for 
transmission of pneumococci to older age 
strengths and limitations of this study
 ► We describe a novel application of study methods 
that enable monitoring the indirect effects of pneu-
mococcal conjugate vaccines using pneumococcal 
carriage and in the absence of baseline data.
 ► The methods do not measure indirect protection 
against disease. However, a reduction in vac-
cine-type  (VT) carriage among undervaccinated 
cases suggests likely reductions in VT disease, 
since carriage is a precursor for disease The use of 
molecular serotyping microarray enables detection 
of multiple serotype carriage and serotype-specific 
carriage density.
 ► The inclusion of three sites, which have contrasting 
vaccine schedules and pneumococcal epidemiolo-
gy, will enable us to explore factors that may modify 
the vaccine coverage required to achieve indirect 
effects; however, variations in methods and set-
tings may impact on the comparability of our results 
across the three sites.
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groups,2 3 and is a precursor for disease.4 There are over 
90 known serotypes of pneumococci, with differing capac-
ities for causing disease.5 
The introduction of the pneumococcal conjugate 
vaccine (PCV) has resulted in substantial reductions in 
pneumococcal disease in many settings.6 These reduc-
tions are mediated by direct effects on vaccinated children 
as well as indirect effects on undervaccinated children 
and adults through a reduction in transmission and 
subsequent nasopharyngeal (NP) carriage of pneumo-
coccal serotypes included in the vaccine.7–10 The indirect 
effects account for a substantial component of the overall 
vaccine effect. Following the introduction of the 7-valent 
PCV (PCV7) into the routine vaccination programme 
in the USA, twice as many invasive cases were prevented 
through indirect effects compared with direct effects.11
The magnitude of indirect effects following introduc-
tion of PCV varies considerably by setting. Reductions 
in invasive pneumococcal disease (IPD) among adults 
ranged from 8.8% among adults in Denmark 3 years after 
PCV implementation to 70% reduction among adults in 
Taiwan 7 years after PCV implementation.12 A review of 
the literature found that higher vaccine coverage, higher 
baseline rates of pneumococcal disease and greater time 
elapsed since PCV introduction were all associated with 
greater degrees of indirect effects.12 However, the majority 
of these studies were conducted in high-income country 
settings using a similar vaccine schedule, with relatively 
high levels of vaccine coverage.
The threshold of vaccination coverage required to 
achieve significant indirect PCV effects on either pneu-
mococcal carriage or disease outcomes are not well 
understood. Studies of NP carriage indicate that there 
is variability in the coverage required to achieve signifi-
cant indirect effects. Two studies in the USA examined 
this question for the 13-valent PCV (PCV13) that super-
seded PCV7 immunisation. A vaccine coverage of 58% 
among American Indian children in southwestern USA 
and 75% coverage among children in Massachusetts 
resulted in a 50% decline in the prevalence of carriage 
of six PCV13 serotypes (ie, PCV13 types not included in 
PCV7) carried by undervaccinated children.13 14 The USA 
uses a 3+1 schedule (three primary doses with a booster) 
and had a catch-up programme up to 5 years of age. Many 
LMIC use a 3+0 schedule.15 More data are needed from 
a range of LMIC to determine the vaccination coverage 
required to achieve indirect protection from PCVs and to 
determine factors that may modify the vaccine coverage 
required for indirect effects, such as baseline carriage 
prevalence, indicating intensity of transmission, vaccine 
schedules and use of catch-up campaigns.
Existing systematic reviews indicate that vaccine sched-
ules do not impact on the degree of indirect effects on 
IPD; however, the studies included in these reviews 
predominantly use a 3+1 schedule or a 2+1 schedule (two 
primary doses with a booster) and have limited studies 
using PCV13.12 16 Few studies using the 3+0 schedule 
(three primary doses with no booster) are available 
in the published literature, despite the 3+0 schedule 
being widely used, especially in LMIC. A recent study 
from Australia, the only high-income country to use the 
3+0 schedule, concluded that the booster dose may be 
important for obtaining indirect protection because of 
the lower indirect effects observed compared with other 
high-income country settings.17
Despite the gradual introduction of PCVs in LMIC over 
the last decade, there have been few studies published on 
the impacts of PCV in these settings.18 19 This is because 
the predominant method for assessing vaccine impact, 
IPD surveillance, is costly and resource intensive to estab-
lish—requiring laboratory capacity as well as the collec-
tion of large numbers of samples, obtained using aseptic 
techniques, in order to detect a relatively rare outcome.20 
Furthermore, baseline data prior to vaccine introduction 
required for impact evaluations are often not available in 
these settings.
In the absence of IPD surveillance, LMIC require a 
method to evaluate direct and indirect vaccine effects. We 
propose using NP carriage surveillance in children hospi-
talised with acute respiratory infection (ARI) to monitor 
the indirect effects of PCV13 in the study called PNEU-
mococcal CArriage in Pneumonia To Investigate Vaccine 
Effects (PneuCAPTIVE).
In this context, we refer to ‘carriage’ as the detection 
of pneumococci in the nasopharynx of a child with ARI. 
A reduction in vaccine-type (VT) pneumococcal carriage 
suggests likely reductions in disease due to VT pneumo-
cocci, since carriage is a precursor to disease.4 Existing 
studies among healthy children have demonstrated 
reductions in VT carriage following PCV introduction, 
while overall carriage remains stable due to replacement 
with non-vaccine type (NVT) carriage.21 22
We aim to determine the PCV13 coverage required 
to demonstrate substantial indirect effects of PCV using 
NP carriage surveillance in children hospitalised with 
ARI in three settings within Asia and the Pacific. We are 
focusing on children under 5 years of age because studies 
have shown that children are the main reservoir for pneu-
mococci, and reductions in transmission within this age 
group are likely to result in reductions in VT carriage 
among older age groups.2 3 23
As this is a novel method for determining indirect 
effects, we will also aim to determine whether changes in 
patterns of VT and NVT pneumococcal carriage among 
children with ARI are reflective of changes in serotypes 
circulating in the community, noting that carriage in 
our cohort may be more reflective of serotypes causing 
disease.5 24
objECtIvEs
Our objectives are to: (1) investigate the relationship 
between PCV13 coverage and VT carriage among under-
vaccinated cases, defined as children (indirect effects) 
aged 2–59 months with an ARI in Lao People’s Demo-
cratic Republic (Lao PDR), Mongolia and Papua New 
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Guinea (PNG); (2) describe monthly trends in VT 
carriage prevalence among cases and contacts. Contacts 
are defined as children 0–59 months of age, who have 
slept in the same house as or played with the case during 
the preceding 3 weeks; (3) investigate the relationship 
between PCV13 coverage and VT carriage among under-
vaccinated contacts (indirect effects) and caregivers living 
in the community; and (4) compare the PCV13 coverage 
required to demonstrate indirect effects of PCV13 by site 
and determine the degree to which site-specific factors, 
such as pneumococcal carriage rates and densities, 
vaccine schedule and use of catch-up campaigns, account 
for differences in the PCV13 coverage required to demon-
strate indirect effects.
MEthods
study design
We are conducting prospective hospital-based observa-
tional studies in Lao PDR, Mongolia and PNG. We are 
recruiting children 2–59 months of age presenting with 
ARI and obtaining NP swabs to determine prevalence and 
density of VT carriage. We are determining the PCV13 
status of each case using written record. Recruitment will 
occur over at least 3 years and up to 5 years post-PCV13 
introduction at each site.
Concurrently, we are determining vaccination coverage 
at the resident village or subdistrict of each recruited case, 
using either administrative data or vaccination coverage 
surveys.
study settings
Lao PDR site
The Lao PDR PneuCAPTIVE study is embedded within 
a hospital-based study of ARI aetiology, in collabora-
tion with Lao Oxford Mahosot Hospital-Wellcome Trust 
Research Unit, the WHO and the Lao PDR Ministry of 
Health.25 PCV13 was introduced in October 2013, using a 
3+0 schedule at 6, 10 and 14 weeks of age and a catch-up 
programme up to 12 months of age (table 1). We are 
recruiting cases at Mahosot Hospital, one of the largest 
paediatric referral hospitals in Vientiane, the capital of 
Lao PDR. Recruitment started in December 2013.
Mongolia site
The Mongolian PneuCAPTIVE study is embedded 
within a hospital-based paediatric pneumonia surveil-
lance program to determine vaccine impact, which is 
conducted in partnership between the Murdoch Chil-
dren’s Research Institute (MCRI), WHO and the Mongo-
lian Ministry of Health. PCV13 was introduced in June 
2016, using a modified 2+1 schedule at 2, 4 and 9 months 
of age, within the two ‘Phase 1’ districts within Ulaan-
baatar, the capital of Mongolia as part of a phased intro-
duction (table 1), with a catch-up programme of two 
doses 1 month apart for those up to 24 months of age. We 
are recruiting cases, residing in the two phase 1 districts, 
at the two district hospitals and the tertiary referral paedi-
atric hospital for Mongolia, the Maternal and Child 
Hospital. Sampling started November 2015.
PNG site
The PNG PneuCAPTIVE study represents a collaboration 
between the PNG Institute of Medical Research, Tele-
thon Kids Institute, the University of Western Australia 
and MCRI. It is an extension of a pneumonia aetiology 
study that commenced in 2013.26 PCV13 was introduced 
to PNG in October 2014 using a 3+0 schedule at 1, 2 and 3 
months of age (table 1); however, it was not widely distrib-
uted in the Eastern Highlands Province until late 2015. 
We are recruiting cases at the Eastern Highlands Provin-
cial Hospital, the major referral hospital for the Eastern 
Highland Province, as well as nearby clinics in Goroka, 
the capital of the Eastern Highlands Province. Recruit-
ment started April 2016. In PNG, we are also recruiting 
caregivers, as well as contacts, defined as children 0–59 
months of age, who have slept in the same house as or 
played with the case during the preceding 3 weeks. This 
will enable us to determine whether changes in patterns 
of VT pneumococcal carriage in the hospitalised cases are 
reflective of changes within the community, as well as to 
examine indirect effects in the adult age group.
Case recruitment and data collection
Participant recruitment and data collection are consistent 
across the three sites; however, there are some local adap-
tations to the protocol at each site, which are summarised 
in table 2. These adaptations are due to the PneuCAP-
TIVE study being nested within other existing studies, 
described above.
Cases are eligible for inclusion in the PneuCAPTIVE 
study if they are 2–59 months of age and presenting 
with ARI (defined in table 2 below). All cases with fever 
or respiratory symptoms are screened for inclusion. In 
Mongolia, we are restricting recruitment to patients living 
within the two ‘Phase 1’ districts that have commenced 
Table 1 Key aspects of the 13-valent pneumococcal 
conjugate vaccination (PCV13) programme by site, Lao 
People’s Democratic Republic (PDR), Mongolia and Papua 
New Guinea (PNG)
Lao PDR Mongolia PNG
Year of PCV13 
introduction
October 
2013
June 2016 October 
2014
Location 
of PCV13 
introduction
National Two districts in 
Ulaanbaatar
National
PCV13 
schedule
3+0 
(6, 10 and 
14 weeks)
2+1 (2, 4 and 
9 months)
3+0 (1, 
2 and 
3 months)
Presence of 
a catch-up 
programme
Catch-up 
of three 
doses up to 
12 months of 
age
Catch-up of two 
doses 2 months 
apart up to 
24 months of 
age
None
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PCV13 in 2016. In PNG, we are restricting recruitment 
to patients living within 1 hour of the town as follow-up is 
logistically challenging.
Regarding recruitment, in Lao PDR, study staff are 
screening potential recruits from Monday to Friday each 
week. However, they are obtaining clinical information 
from medical records for all eligible cases, including 
those admitted at weekends to ensure we have a repre-
sentative sample. In Mongolia, caregivers of all eligible 
children presenting to the hospital will be approached 
for recruitment as part of the larger PCV impact study. 
However, for the purposes of this study, we will select a 
random sample of 33 cases per month for microbiolog-
ical testing. In PNG recruitment takes place 4–5 days per 
week.
After determining eligibility and obtaining informed 
parental consent, we complete a questionnaire to obtain: 
demographic data, clinical data, PCV13 status and risk 
factors for vaccination and NP carriage, including prior 
antibiotic use (see analysis section below for complete 
list). Vaccination status is determined using written 
records, either parent-held immunisation records or 
health centre administrative records.
We then collect an NP swab according to WHO guide-
lines and store it in 1 mL skim milk tryptone glucose glyc-
erol (STGG) medium.27 Swabs are vortexed, aliquoted 
and stored frozen at −80°C within 8 hours of collection 
and transported from all three sites to the Pneumococcal 
Research laboratory at MCRI on dry ice or in liquid 
nitrogen, where they will be stored at −80°C.
Laboratory methods
All samples are screened for the presence of pneumo-
cocci using real-time quantitative PCR (qPCR) assay 
targeting the pneumococcal lytA gene.22 Genomic DNA 
are extracted from 100 µL of STGG using a MagNA Pure 
LC Machine (Roche) using the DNA Isolation Kit III 
(Bacteria, Fungi) (Roche) following an enzymatic lysis 
treatment. The pneumococcal load is estimated by refer-
ence to a standard curve.
All swabs that are lytA positive or equivocal are molec-
ular serotyped using BµG@S Senti-SP v1.5 microarray 
(BUGS Bioscience) as previously described.28
Serotype-specific pneumococcal density is calculated 
using the relative abundance of each serotype identified, 
as determined using microarray and interpreted with the 
assistance of a Bayesian random effects model as previ-
ously described,28 29 and the overall pneumococcal load 
as determined by the lytA qPCR.
Key definitions
The primary outcome, VT carriage, is defined as the NP 
carriage of at least one pneumococcal serotype included 
in the PCV13 vaccine, that is, serotypes 1, 3, 4, 5, 6A, 
6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. In the context of 
multiple serotype carriage, VT carriage will be defined as 
the presence of at least one VT serotype regardless of the 
presence of other serotypes. A secondary outcome is VT 
carriage density (CFU/mL), which is defined as an aggre-
gate of the serotype-specific density for each of the VTs 
carried by the case, and will be reported as a continuous 
Table 2 Patient eligibility by site: Lao People’s Democratic Republic (PDR), Mongolia and Papua New Guinea (PNG)
Site Lao PDR Mongolia PNG
Inclusion criteria 2–59 months of age and presenting with:
Definition of acute 
respiratory infection
Fever (parent report or 
measured) AND one of cough 
OR dyspnoea OR rhinitis OR 
abnormal chest auscultation
Cough OR dyspnoea AND tachypnoea* 
OR hypoxia OR chest indrawing
Cough AND tachypnoea* AND 
lower chest wall indrawing
Exclusion criteria – Lives outside phase 1 district.
Admitted with pneumonia in the last 
14 days.
Lives ≥1 hour outside town OR 
hospitalisation in past 14 days
Recruitment site Inpatient setting only Inpatient setting only Inpatient and outpatient 
setting
Sampling Monday–Friday A random sample (33 per month) of all 
enrolled cases are selected for testing.
Monday–Friday
Sampling period December 2013–November 
2019
November 2015–October 2018† April 2016–March 2019
Study population Mahosot Hospital is one of 
two tertiary-level paediatric 
hospitals in Vientiane and 
receives a mix of patients 
from urban Vientiane city, rural 
Vientiane province and other 
provinces.
The two secondary–level district 
hospitals and a tertiary-level Maternal 
and Child Health hospital service the 
vast majority of children in the two 
districts that received PCV. There are 
a limited number of paediatric beds at 
private hospitals in Ulaanbaatar.
The Eastern Highlands 
Provincial hospital is the sole 
hospital for the province. 
Study population includes 
urban and rural households 
within 1-hour drive of Goroka.
*Tachypnoea is defined as ≥50 breaths per minute.
†A 1-year extension (until June 2019) has been sought for the Mongolian site.
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variable using a log scale to account for large variations in 
density and a skewed distribution.
Vaccine history will be defined based on documented 
evidence of receiving an adequate number of PCV doses 
to provide a protective immune response against vaccine 
serotypes at least 14 days prior to study enrolment.30 For 
children <12 months of age, ‘vaccinated’ is defined as two 
or more PCV13 doses. For children 12 months of age or 
older, ‘vaccinated’ is defined as receipt of two doses in 
the first year of life or at least one dose after the age of 
12 months. Conversely, a case will be defined as ‘under-
vaccinated’ if they have received less than the adequate 
number of PCV doses (including those never vaccinated). 
Sensitivity analyses will be conducted using varying defini-
tions of vaccinated including receiving at least one dose 
of vaccine at any age.
vaccine coverage data collection
For each undervaccinated case recruited (including 
those with and without VT pneumococci), we are deter-
mining their resident village or subdistrict vaccina-
tion coverage. In Mongolia and Lao PDR, we are using 
administrative data. The resident village or subdistrict 
is identified using relevant administrative codes, which 
are determined by local staff on enrolment. This deter-
mines the health centre’s administrative boundary for 
the provision of immunisation services, whereas in PNG, 
we are conducting community surveys within 10 days of 
discharge in the village where the case is living (table 3). 
We are surveying all children less than 5 years of age, from 
households within 10–20 min walk of the case, since this is 
the group of children with whom the case is mostly likely 
to interact and therefore influence their carriage status.
To determine the reliability of our methods in Lao 
PDR, we plan on comparing our coverage estimates with 
a National Immunisation Survey, conducted according to 
WHO guidelines in 2015, when provincial level estimates 
from this survey become available. In Mongolia, we have 
validated the newly introduced electronic immunisation 
record against clinic health records, finding a high degree 
of concordance.31 We are also in the process of validating 
the population registers at health centres in Mongolia.
data management
In Lao PDR and Mongolia, study staff are double-en-
tering data using Research Electronic Data Capture 
and Microsoft Access (Microsoft Corporation) database, 
respectively. In PNG, data are checked by a monitor prior 
to being entered into Filemaker Pro (FileMaker). We are 
conducting regular double-entry discrepancy checks and 
logic checks using Stata Statistical Software.
Analysis
All analyses will be completed using Stata Statistical Soft-
ware. We will summarise continuous variables using mean 
and SD (or median and IQR for non-symmetrical data). 
Categorical variables will be summarised using frequency 
counts and percentages.
Objective 1: relationship between vaccine coverage and indirect 
effects
We want to investigate the relationship between VT 
carriage and density among undervaccinated cases 
(indirect effects) and subdistrict/village PCV coverage. 
We will use an adaptation of a method used to esti-
mate indirect protection for an oral cholera vaccine, 
which exploits heterogeneities in vaccine coverage at 
the subdistrict/village level, comparing VT carriage 
and density among undervaccinated children from 
subdistricts/villages with differing levels of vaccine 
coverage.32 33
This will be done using multivariable models with VT 
carriage or density in ARI cases as the outcome variable 
and PCV coverage at the child’s place of residence at 
the time of admission as the exposure variable. We will 
use generalised estimating equations to account for clus-
tering at the subdistrict/village level.
To identify confounders for adjustment, we have 
constructed a directed acyclic graph (DAG). DAGs 
include all variables potentially related to exposure and 
outcome, connected using unidirectional arrows showing 
causal relationships between variables. The graph identi-
fies potentially confounding pathways and allows investi-
gators to determine variables that should be controlled 
for to obtain unbiased effect estimates. As there are likely 
to be unique confounders between sites, we will develop 
site-specific DAGs. We will use  DAGitty. net (V.2.3) soft-
ware to identify minimally sufficient confounding subsets 
for adjustment.
For each site, we will construct a similar model using 
overall pneumococcal carriage as the dependent variable. 
This model will act as a bias indicator since PCV coverage 
is not expected to affect levels of overall pneumococcal 
carriage due to replacement carriage with NVTs, although 
complete replacement to baseline levels can take several 
years.21 34 35 Therefore, we will restrict this analysis to the 
latter part of the study period, when descriptive analyses 
indicate the replacement is complete.
Table 3 Vaccination coverage data by site, Lao People’s 
Democratic Republic (PDR), Mongolia and Papua New 
Guinea
Site Lao PDR Mongolia
Papua New 
Guinea
Source of 
numerator 
data
Health 
centre 
records
Electronic 
immunisation 
record
Community 
surveys
Source of 
denominator 
data
Lao PDR 
Population 
and Housing 
Census 
2015
Health centre 
population 
register*
*All children are required to be registered at the health centre 
servicing their resident subdistrict in order to receive health 
services.
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To determine whether a higher PCV coverage is 
required to achieve indirect effects among completely 
unvaccinated cases compared with undervaccinated cases, 
we will conduct a sensitivity analysis among children who 
have never received PCV.
Objective 2: VT carriage prevalence among cases and contacts by 
calendar month (PNG only)
Crude and adjusted monthly VT carriage prevalence will 
be estimated within rolling 7-month intervals to present 
smooth curves and assess trends over time. This will be 
done separately for cases and contacts. To account for 
differences in age between cases and community contacts, 
the carriage prevalence will be adjusted using direct stan-
dardisation (standardised to the case population over the 
entire study period).
Objective 3: relationship between vaccine coverage and indirect 
effects among community contacts (PNG only)
To investigate whether relationship between vaccine 
coverage and indirect effects as observed among cases 
with ARI are reflective of the relationship between vaccine 
coverage and indirect effects in the wider community, we 
will apply the same model described above to undervacci-
nated community contacts. We will construct multivariable 
models with VT carriage and density among undervacci-
nated community contacts as the outcome variable and 
PCV coverage at the child’s place of residence at the time 
of admission as the exposure variable. We will be using 
the same vaccine coverage data as for the cases.
Objective 4: comparison of vaccine coverage required for indirect 
effects across sites
We will compare differences in the PCV13 coverage 
required to demonstrate indirect effects of PCV13 quali-
tatively by site and in relation to vaccine schedule and use 
of catch-up campaigns. Inferential statistics are unlikely 
to be suitable with the inclusion of only three sites, and 
comparability between sites is limited due to variations 
between them.
Power calculation
Power calculations were performed using nQuery Advi-
sor+nTerim 4.0. Calculations were based on sample size 
methods for logistic regression models with a continuous 
covariate (ie, PCV coverage) and additional covariates, 
with inflation to account for clustering within villages. 
Power calculations assumed VT carriage prevalence of 
30% in Lao PDR and 40% in Mongolia and PNG at the 
mean PCV coverage level36 and VT carriage prevalence 
of 20% in Lao PDR and 30% in Mongolia and PNG at 
1 SD above the mean PCV coverage level. Assuming a 
significance level of 0.05, allowing for adjustment using 
multiple covariates with an R2 of 0.4, and that 50% of the 
cases are undervaccinated, a sample size of 1200 cases per 
site would provide between 87% and 92% power to deter-
mine the proportion of cases carrying VT pneumococcus 
at varying levels of village vaccine coverage. The power 
calculation has been adjusted to account for clustering 
by village, with higher variability in Lao PDR and PNG 
(intraclass coefficient (ICC) 0.1) and lower variability in 
Mongolia (ICC 0.01).
Missing data
We will describe the number of participants with missing 
data on individual variables and compare the characteris-
tics of those with and without missing data to determine 
whether there is evidence of systematic differences in char-
acteristics. If we determine that the differences observed 
are able to be explained by available data (ie, missing at 
random), we will consider using multiple imputation to 
predict the distribution of the missing data in order to 
account for the bias due to incomplete data.37
Patient and public involvement
Patients were not involved in the design of this study. 
Public health authorities in Laos and Mongolia were 
involved in the design and conduct of the study. In PNG, 
village representatives are approached to ensure that 
community surveys are conducted appropriately.
Current status of the study
Recruitment is ongoing, and analysis of data, followed 
by publication of results, is expected from 2018 onwards. 
As of August 2017, we have recruited 1039, 481 and 3847 
cases from Lao PDR, PNG and Mongolia, respectively. 
Table 4 describes the baseline characteristics of the chil-
dren recruited.
Ethics and dissemination
Prospective participants will be fully informed about the 
potential risks and benefits of participation, and written 
informed consent will be obtained prior to recruitment. 
We plan on disseminating results to relevant stake-
holders within Lao PDR, PNG and Mongolia, as well 
as submitting our findings for publication in relevant 
peer-reviewed journals and conferences.
dIsCussIon
The ability for LMICto monitor the indirect effects of 
PCV is critical. Maximising indirect effects is important 
because these effects comprise a substantial proportion of 
overall PCV impact and increase the cost-effectiveness of 
the vaccine.38 Indirect protection is particularly important 
for individuals who are unable to be vaccinated or who 
have poor vaccine responses, such as infants too young 
to be vaccinated and the elderly. In addition, the Bill & 
Melinda Gates Foundation is supporting studies looking 
into the effectiveness of reduced dose schedules (1+1). 
This reduced dose schedule needs to maintain indirect 
effects following PCV introduction, and this surveillance 
method provides a mechanism to determine when herd 
protection has been achieved and whether it is main-
tained.39 Furthermore, the ability to determine whether 
substantial herd protection has been achieved may help 
to identify settings that are appropriate for introduction 
of reduced dose or modified schedules.
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The results of our study will address the scarcity of liter-
ature determining the PCV coverage required to achieve 
substantial indirect effects, especially in LMIC. The 
inclusion of three sites, which have contrasting vaccine 
schedules, baseline intensities of pneumococcal carriage 
and healthcare systems, will also enable us to determine 
whether this vaccine coverage threshold differs by site 
and explore factors that may modify the vaccine coverage 
required to achieve indirect effects.
In this proposal, we describe a novel application of an 
analysis method to measure indirect effects. Although 
the isolation of a particular pneumococcal serotype from 
the nasopharynx of a child with ARI is not necessarily 
indicative of the serotype causing pneumococcal disease, 
reduced detection of VT pneumococci is likely to reflect 
reductions in disease due to VT pneumococci. Further-
more, our proposed analysis methods enable estimation 
of indirect effects in the absence of baseline pre-PCV data. 
This will be relevant for many LMIC that have little or no 
baseline data and are considering options for surveillance 
to accompany the introduction of PCV.
Another key strength of our methods is the use of consis-
tent molecular serotyping microarray methods across 
all three sites, enabling sensitive detection of multiple 
serotype carriage and ascertainment of serotype-specific 
density.28 Conventional pneumococcal carriage studies 
typically detect the presence of a single serotype and may 
overlook the presence of vaccine serotypes occurring at 
lower densities. The results of this study will also add to 
the limited literature on the effects of PCV on VT carriage 
density, which may affect likelihood of transmission.40
Our proposed methods have several potential limita-
tions. First, there are significant challenges in determining 
accurate estimates of PCV coverage in resource-limited 
settings. In Mongolia and Lao PDR, where we are using 
administrative data, our estimates rely on the availability 
of accurate data about vaccine doses administered 
(numerator) as well as population estimates for the 
target age group (denominator). In both settings, we are 
conducting audits to assess the reliability of numerator 
data. Regarding denominator data, we are fortunate that 
a recent population census was conducted in Lao PDR in 
March 2015. However, we will be auditing denominator 
data in Mongolia, where population estimates are affected 
by large seasonal population movements between rural 
and urban settings. In PNG, the validity of the community 
surveys depends on representative sampling. However, 
survey participation can vary and is affected by season 
(related to farming practices), as well as community trust 
and understanding of the study. To maximise participa-
tion, we conducted mobile health clinics alongside the 
community surveys.
The second main limitation relates to detecting pneu-
mococcal carriage in our study population of children 
hospitalised with respiratory infection. In this population, 
carriage detection may be affected by the prior use of 
antibiotics.41 42 To address this, we have, where possible, 
aimed to recruit patients at admission, prior to receiving 
antibiotics or documented prior antibiotic use, which will 
be taken into account during analysis.
Third, there are variations in methods and setting 
across the three sites. This limitation may impact on the 
comparability of our results across the three sites. The 
reason for the differences in methods between sites is that 
our study is built on pre-existing studies (pneumonia aeti-
ology studies in Lao PDR and PNG and a vaccine impact 
study in Mongolia) with established protocols.
To conclude, the results of this study will provide 
important feedback to national policy makers about the 
effects of newly introduced PCV programmes in Lao PDR, 
Mongolia and PNG. The results will help us understand 
the determinants of indirect effects and therefore guide 
strategies to maximise them. In particular, the results 
will also inform global policy about the vaccine coverage 
required to achieve substantial indirect effects in settings 
with different epidemiological characteristics of pneumo-
coccal disease and carriage and will maximise the cost-ef-
fectiveness of the vaccine programmes.
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